Fisher Scientific Group Signs License Agreement

Fisher Scientific Group has signed an exclusive licensing agreement with ImClone Systems Inc., a New York-based, biotechnology company, to manufacture and market a range of tests that will diagnose the presence of Hepatitis B, AIDS, cancer and viral infections. The first test, for Hepatitis B, is expected to go to market in 1988.

The joint venture will “enable Fisher to make a strong entry into the most rapidly growing segment of the clinical diagnostic market,” according to Fisher Chairman and Chief Executive Richard A. Kramer.”